Create Free Account

By creating account you will get access to hot stocks & personalised emails

Cynata Therapeutics Ltd

Healthcare AU CYP

0.19AUD
-0.005(2.56%)

Last update at 2025-05-09T01:39:00Z

Day Range

0.190.20
LowHigh

52 Week Range

0.140.34
LowHigh

Fundamentals

  • Previous Close 0.20
  • Market Cap45.19M
  • Volume104210
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.06217M
  • Revenue TTM1.74M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 1.74M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -14.27750M -5.44517M -7.68968M -3.63910M -8.47215M
Minority interest - - - - -
Net income -14.27750M -5.44517M -7.68968M -3.63910M -6.88316M
Selling general administrative 3.18M 3.99M 4.22M 2.47M 2.63M
Selling and marketing expenses 0.06M 0.07M 0.27M 0.47M 0.58M
Gross profit 1.65M 7.77M 1.55M 7.01M 1.31M
Reconciled depreciation 0.28M 0.28M 0.28M 0.28M 0.28M
Ebit -16.54252M -13.83804M -9.08038M -10.51245M -10.06113M
Ebitda -16.26255M -13.55808M -8.80042M -10.23172M -9.78116M
Depreciation and amortization 0.28M 0.28M 0.28M 0.28M 0.28M
Non operating income net other - - - - -
Operating income -14.88821M -6.06762M -7.53433M -3.50090M -10.06113M
Other operating expenses -16.28467M -13.28035M -9.32803M -10.79300M 10.06M
Interest expense - 0.06M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.26M 0.06M 0.09M 0.20M 0.09M
Net interest income 0.35M 0.06M 0.09M 0.14M 0.26M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.35287M -0.06475M -0.09230M -0.14235M -1.58898M
Total revenue 1.65M 7.77M 1.55M 7.01M 0.19M
Total operating expenses 16.54M 13.84M 9.08M 10.51M 10.06M
Cost of revenue - - - - -
Total other income expense net 1.91M 8.33M 1.30M 6.73M 1.59M
Discontinued operations - - - - -
Net income from continuing ops -14.27750M -5.44517M -7.68968M -3.63910M -8.47215M
Net income applicable to common shares -14.27750M -5.44517M -7.68968M -3.63910M -8.47215M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 8.39M 18.99M 26.55M 29.97M 17.48M
Intangible assets - 2.13M 2.41M 2.69M 2.97M
Earning assets - - - - -
Other current assets 0.22M 0.03M 0.24M 0.29M 0.18M
Total liab 1.17M 2.26M 2.59M 1.60M 0.69M
Total stockholder equity 7.22M 16.73M 23.96M 28.37M 16.79M
Deferred long term liab - 2.13M 2.41M 2.69M 2.97M
Other current liab 0.74M 0.95M 1.01M 0.93M 0.39M
Common stock 81.62M 81.62M 74.90M 74.90M 57.17M
Capital stock - 81.62M 74.90M 74.90M 57.17M
Retained earnings -82.31852M -72.57381M -58.29631M -52.85114M -45.16146M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M 2.13M 2.41M 2.69M 3.63M
Cash 6.21M 16.17M 23.80M 26.72M 13.65M
Cash and equivalents - - - - -
Total current liabilities 1.17M 2.26M 2.59M 1.60M 0.69M
Current deferred revenue - - - - -
Net debt -6.20542M -16.16736M -23.79805M -26.71667M -13.64964M
Short term debt - 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - -9.05079M -16.60394M -22.04911M -12.00393M
Property plant equipment - - - - -
Total current assets 6.54M 16.86M 24.14M 27.28M 13.85M
Long term investments - - - - -
Net tangible assets - 16.73M 23.96M 28.37M 16.79M
Short term investments - 0.03M 0.03M 0.03M 0.00357M
Net receivables 0.11M 0.37M 0.10M 0.28M 0.02M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.43M 1.31M 1.58M 0.68M 0.30M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.91M 7.68M 7.36M 6.32M 4.79M
Additional paid in capital - - - - -
Common stock total equity - - - - 57.17M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 0.66M
Deferred long term asset charges - - - - -
Non current assets total 1.85M 2.13M 2.41M 2.69M 3.63M
Capital lease obligations - - - - -
Long term debt total - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments - - - - -
Change to liabilities -0.25998M 0.95M 0.74M -0.78091M 0.53M
Total cashflows from investing activities - - - - 0.00000M
Net borrowings - - - - -
Total cash from financing activities 6.72M 0.21M 18.20M 10.06M 1.53M
Change to operating activities -0.06768M 0.03M 0.17M 0.01M 0.02M
Net income -14.27750M -5.44517M -7.68968M -3.63910M -6.88316M
Change in cash -7.63069M -2.91862M 13.07M 6.67M -5.22865M
Begin period cash flow 23.80M 26.72M 13.65M 6.98M 12.21M
End period cash flow 16.17M 23.80M 26.72M 13.65M 6.98M
Total cash from operating activities -14.28273M -3.29833M -5.16311M -3.38768M -6.75908M
Issuance of capital stock 7.04M - 18.31M 9.38M 1.41M
Depreciation 0.28M 0.28M 0.28M 0.28M 0.28M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.35639M 0.02M -0.15668M 0.15M 0.04M
Sale purchase of stock -0.31782M -0.31782M -0.57195M -0.40692M -0.07551M
Other cashflows from financing activities -0.31782M 0.21M 0.46M 1.08M 0.20M
Change to netincome 0.40M 0.86M 1.49M 0.59M 0.84M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.35639M 0.02M -0.15668M 0.15M -3.56680M
Stock based compensation 0.33M 1.03M 1.54M 0.39M -
Other non cash items -0.28520M 1.87M 2.25M -0.02931M 8.19M
Free cash flow -14.28273M -3.29833M -5.16311M -3.38768M -6.75908M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CYP
Cynata Therapeutics Ltd		 -0.005 2.56% 0.19 - - 25.97 3.93 - -1.7342
CSL
CSL Ltd		 -1.39 0.58% 238.53 28.83 34.60 7.97 4.21 6.03 18.72
TLX
Telix Pharmaceuticals Ltd		 0.35 1.31% 26.97 186.60 64.10 11.96 16.49 11.80 99.84
MSB
Mesoblast Ltd		 -0.04 2.29% 1.71 - 454.55 422.65 3.18 274.03 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 0.47 3.67% 13.27 10.70 68.49 7.01 4.10 5.96 7.23

Reports Covered

Stock Research & News

View All

Profile

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

Cynata Therapeutics Ltd

100 Cubitt Street, Cremorne, VIC, Australia, 3121

  • 61 3 7067 6940

Key Executives

Name Title Year Born
Dr. Ross Alexander MacDonald Ph.D. MD, CEO & Exec. Director 1958
Dr. Kilian Kelly Chief Operating Officer NA
Dr. Jolanta Airey Chief Medical Officer NA
Dr. Suzanne Lipe VP of Alliance Management 1950
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963
Dr. Kilian Kelly MD, CEO & Director NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary 1963
Dr. Kilian Kelly MD, CEO & Director NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary 1963
Dr. Kilian Kelly MD, CEO & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

Market Research
ISO Certified pcidss

Kalkine Solutions Private Limited, an authorized representative of Kalkine Pty Ltd, holds the ISO 27001:2022 certification (Certificate No. IC-IS-2404072) and the PCI-DSS Version 4.0 Level 1 certification (Certificate No. CSNL1PCI8067).

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2025 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.